Watch this webinar from Philippe Ledent, Chief Scientific Director at Xpress Biologics, now part of Sartorius and Rakel Lopez de Maturana, Qualified Person & Regulatory Affairs Director at VIVEbiotech discuss how to ensure gain of time and success of lentiviral-based therapies from process development up to market approval.

Key Learning Objectives:

• Meeting regulatory compliance for plasmids used for lentivirus manufacturing.
• Ensuring same manufacturing process and specifications for research to GMP grade plasmid manufacturing.
• Adaptable plasmid manufacturing platform is critical to accelerate lentivirus manufacturing